CERo Therapeutics
CERO
CERO was delisted on the 30th of October, 2025.
0 hedge funds and large institutions have $0 invested in CERo Therapeutics in 2025 Q4 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 11 closing their positions.
100% less funds holding
Funds holding: 11 → 0 (-11)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
100% less capital invested
Capital invested by funds: $799K → $0 (-$799K)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 11
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PA
Parallel Advisors
San Francisco,
California
|
-$616K |
| 2 |
AVM
Arch Venture Management
Chicago,
Illinois
|
-$114K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$52.1K |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
-$6.61K |
| 5 |
FIA
FNY Investment Advisers
New York
|
-$5K |
CERO Hedge Fund Activity: Q4 2025 in Review
0 of the 8,281 institutional investors tracked by Wall St. Rank reported a position in CERo Therapeutics (CERO) for Q4 2025, worth a combined $0 — down 100% from $799K a quarter earlier.
Sellers outnumbered buyers: 11 funds closed out of CERO and 0 opened new positions — a net loss of 11 holders — while 0 trimmed existing stakes and 0 added.
The largest seller was Parallel Advisors, exiting entirely with an estimated $616K sold.
- 0 institutional investors held CERo Therapeutics (CERO) as of Q4 2025, down from 11 in Q3 2025.
- Funds reported $0 of CERo Therapeutics stock for Q4 2025, down 100% quarter-over-quarter.
- 0 funds opened new CERo Therapeutics positions in Q4 2025 and 11 closed out, a net change of -11 holders.
- The largest CERo Therapeutics seller in Q4 2025 was Parallel Advisors, an estimated $616K sold.
Based on aggregated 13F filings for Q4 2025.